HHS Calls for Revised Labels on Testosterone Therapies, Citing New Safety Data
The US Department of Health and Human Services (HHS) has requested revisions to the labels on testosterone replacement therapies for men, following a review of new safety and efficacy data. The requested changes include removing a statement that safety and effectiveness have not been established in men with age-related low testosterone, updating information on prostate cancer risk, and revising warnings regarding benign prostatic hyperplasia.
Key Findings and Label Changes
- Cardiovascular safety: A clinical study involving over 5,200 men found no meaningful increase in major cardiovascular events (heart attack, stroke) among those receiving testosterone therapy.
- Prostate cancer risk: Updated labels would advise against therapy only in men with metastatic prostate cancer, as recent data have not shown an increased risk of prostate cancer in men receiving therapy.
- Benign prostatic hyperplasia: An FDA review found no evidence that testosterone therapy worsens symptoms in men with mild to moderate enlarged prostate; monitoring is still recommended for severe cases.
"The updates aim to provide clearer information for informed medical decisions." – HHS Secretary Robert F. Kennedy Jr.
Background
In 2015, the FDA required label changes citing limited evidence of benefit and possible cardiovascular risks for men with idiopathic hypogonadism. The current request is part of the Trump administration's efforts to reduce restrictions on hormone therapies, following similar steps for menopausal hormone therapy in 2024.
Clinical Perspectives
- Dr. Jamin Brahmbhatt (urologist, Orlando Health) noted that the proposal does not mean every man should use testosterone therapy; it remains a medical treatment requiring proper diagnosis and monitoring.
- Dr. Adam Baumgarten (University of Alabama at Birmingham) said the cardiovascular safety concerns are no longer supported by randomized trial data, but the changes do not signal indiscriminate use.
Clinical Context
Healthcare providers generally consider testosterone levels below 300 ng/dL as low in adults, but normal levels vary with age and guidelines. Proper diagnosis requires two separate morning blood draws confirming low levels in conjunction with symptoms such as low sex drive, fatigue, or loss of muscle.
Potential Risks and Side Effects
Therapy may include skin reactions, acne, enlargement of male breast tissue, pulmonary embolism, blood clots, irregular heart rhythms, suppression of sperm production, and minimal increase in blood pressure.